Business context and reporting period
Filing identity mismatch: The metadata names Calidi Biotherapeutics, Inc., but the supplied 10-K is for First Light Acquisition Group, Inc. (NYSE: FLAG, FLAGU, FLAGW). This summary reflects the filing text, not Calidi.
First Light was a blank-check company formed in March 2021 to pursue a business combination. It had no operating business and had not identified a target or begun substantive discussions by December 31, 2021. The financial statements cover March 24, 2021 (inception) through December 31, 2021; they do not provide a standalone fourth-quarter comparison.
Financial results and liquidity
| Metric | Reported amount or status |
|---|---|
| Revenue | None; no operations or operating revenue to date. |
| Operating costs / operating loss | $1.782 million / $(1.782) million. |
| Net income | $3.387 million, primarily reflecting a $5.654 million decrease in warrant-liability fair value, partly offset by a $0.490 million increase in forward-purchase-unit liability fair value. This is not evidence of operating profitability. |
| Cash used in operating activities | $1.083 million. |
| Cash and working capital outside trust | Cash of $1.063 million and working capital of $1.073 million at year-end. |
| Trust account | $230.005 million in cash and marketable securities, restricted principally to a business combination or specified redemptions. |
| Total assets / total liabilities | $231.769 million / $16.451 million. Liabilities include $8.050 million of deferred underwriting fees, $7.469 million warrant liability and $0.521 million forward-purchase-unit liability. |
| Debt | No long-term debt reported; the $188,804 sponsor promissory note was repaid at the IPO closing. |
First Light sold 23 million units at $10 each in September 2021, placing $230 million in trust. It also raised approximately $5.096 million from private-placement warrants. Offering costs were approximately $22.517 million. No prior comparable operating period is presented.
Outlook, risks and unusual items
- The company intended to seek a technology-enabled business, with stated interest in aerospace, space, microelectronics, cybersecurity, power and energy, and autonomy and mobility. It had no specific transaction under consideration.
- A forward-purchase agreement contemplated $50 million of securities at a business-combination closing, but Franklin retained discretion over whether to purchase after receiving transaction information; the funds were therefore not assured.
- The filing and auditor report raise substantial doubt about the company’s ability to continue as a going concern. Management said it expected sponsor working-capital loans if needed, but no formal commitment existed. The company’s ability to execute its plan depended on completing a business combination.
- The deadline was generally 12 months after the September 2021 IPO, with two possible three-month extensions. If no combination were completed within the permitted period, public shares would be redeemed and warrants would expire worthless.
- Management reported ineffective disclosure controls and a material weakness in accounting for warrant and forward-purchase liabilities. The filing says the detected error did not require restatement and did not affect previously issued financial statements; remediation efforts were underway but not assured.
- Key risks include target-search competition, redemptions reducing cash available for a transaction, uncertain financing, conflicts of interest and competing obligations among insiders, creditor claims against trust assets, COVID-19 and market disruptions, and possible effects of Russia-Ukraine tensions.
- Warrants and the forward-purchase agreement were recorded as liabilities and remeasured at fair value, causing potentially volatile non-operating earnings.
Most important facts to verify
- Confirm the issuer: the supplied filing is First Light Acquisition Group, Inc., not Calidi Biotherapeutics, Inc.
- Verify the applicable business-combination deadline, any extensions, and the company’s subsequent transaction status; this filing reports only through December 31, 2021.
- Check whether the contemplated $50 million forward purchase was ultimately funded and review actual redemptions, financing, and cash available at any transaction closing.
- Review subsequent disclosures on remediation of the material weakness and the status of the going-concern uncertainty.
- Distinguish accounting gains from operating performance: the reported net income arose despite no revenue and an operating loss.